---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-039837"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:01:19.342713+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences reports FY2024 net loss of $61.9M; pipeline milestones for 2025

## Summary
- Cash and marketable securities $262.1M as of Dec 31, 2024; expected to fund operations into mid-2027.
- Phase 2 Avail trial of canvuparatide in hypoparathyroidism fully enrolled (64 patients); topline results expected Q3 2025.
- MBX 1416 Phase 1 trial positive; Phase 2 in post-bariatric hypoglycemia to start 2H 2025.
- IND submission for MBX 4291 in obesity anticipated in Q2 2025.
- Net loss for FY2024 was $61.9M vs $32.6M in FY2023, driven by increased R&D and G&A costs.

## SEC filing metadata
- accession: 0000950170-25-039837
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/0000950170-25-039837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/mbx-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-039837
- JSON: https://secwatch.observer/filing/0000950170-25-039837.json
- Plain text: https://secwatch.observer/filing/0000950170-25-039837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.